Literature DB >> 31903287

The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT.

Laura Evangelista1.   

Abstract

Entities:  

Year:  2019        PMID： 31903287      PMCID： PMC6940221          DOI： 10.21037/jtd.2019.10.19

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Is it time to change our vision of tumor metabolism prior to immunotherapy?

Authors:  Fabio Grizzi; Angelo Castello; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-12       Impact factor: 9.236

2.  18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.

Authors:  Laura Evangelista; Lea Cuppari; Jessica Menis; Laura Bonanno; Pasquale Reccia; Stefano Frega; Giulia Pasello
Journal:  Nucl Med Commun       Date:  2019-08       Impact factor: 1.690

3.  18F-fluorodeoxyglucose positron emission tomography is correlated with the pathological necrosis and decreased microvessel density in lung adenocarcinomas.

Authors:  Young Wha Koh; Su Jin Lee; Seong Yong Park
Journal:  Ann Nucl Med       Date:  2018-10-15       Impact factor: 2.668

4.  18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Authors:  Mario Jreige; Igor Letovanec; Kariman Chaba; Stephanie Renaud; Sylvie Rusakiewicz; Valerie Cristina; Solange Peters; Thorsten Krueger; Laurence de Leval; Lana E Kandalaft; Marie Nicod-Lalonde; Pedro Romero; John O Prior; George Coukos; Niklaus Schaefer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-18       Impact factor: 9.236

Review 5.  Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.

Authors:  Abhishek D Garg; Patrizia Agostinis
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

Review 6.  Novel Biomarkers for Personalized Cancer Immunotherapy.

Authors:  Yoshitaro Shindo; Shoichi Hazama; Ryouichi Tsunedomi; Nobuaki Suzuki; Hiroaki Nagano
Journal:  Cancers (Basel)       Date:  2019-08-22       Impact factor: 6.639

7.  Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.

Authors:  Lucas Goldfarb; Boris Duchemann; Kader Chouahnia; Laurent Zelek; Michael Soussan
Journal:  EJNMMI Res       Date:  2019-01-29       Impact factor: 3.138

8.  Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Kazuki Takada; Gouji Toyokawa; Tatsuro Okamoto; Shingo Baba; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Takaki Akamine; Shinkichi Takamori; Masakazu Katsura; Fumihiro Shoji; Hiroshi Honda; Yoshinao Oda; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2017-10-04       Impact factor: 4.452
  8 in total
  1 in total

1.  Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer.

Authors:  Liang Zhao; Peiqiong Chen; Kaili Fu; Jinluan Li; Yaqing Dai; Yuhuan Wang; Yanzhen Zhuang; Long Sun; Haojun Chen; Qin Lin
Journal:  Front Oncol       Date:  2021-02-23       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.